首页 > 最新文献

Global health & medicine最新文献

英文 中文
Current global applications of HBcrAg assays in the management of chronic hepatitis B. HBcrAg检测在慢性乙型肝炎治疗中的全球应用现状
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2025-02-28 DOI: 10.35772/ghm.2024.01097
Takako Inoue, Yasuhito Tanaka

Hepatitis B core-related antigen (HBcrAg) is a vital marker for monitoring chronic hepatitis B (CHB) as it correlates with hepatitis B (HBV) DNA and covalently closed circular DNA (cccDNA). The iTACT-HBcrAg assay, approved in Japan, provides highly sensitive and automated testing, reducing patient burden by requiring smaller specimen volumes and offering shorter processing times. Crucial for managing HBV reactivation and predicting hepatocellular carcinoma, it delivers consistent and reliable results. In resource-limited regions, the HBcrAg-rapid diagnostic test (HBcrAg-RDT) facilitates early HBV detection and management. This point-of-care testing (POCT) tool requires no specialized equipment and provides results within 30 minutes, making it invaluable in areas lacking HBV DNA quantification. Trials in West Africa, Asia, and other developing regions demonstrate its sensitivity and specificity. Together, these advancements in iTACT-HBcrAg and HBcrAg-RDT assays enhance CHB patient care and contribute significantly to the global effort to eliminate HBV as a public health threat.

乙型肝炎核心相关抗原(HBcrAg)是监测慢性乙型肝炎(CHB)的重要标志物,因为它与乙型肝炎(HBV) DNA和共价闭合环状DNA (cccDNA)相关。iTACT-HBcrAg检测在日本获得批准,提供高度敏感和自动化的检测,通过需要更小的样本量和更短的处理时间来减轻患者负担。对于控制HBV再激活和预测肝细胞癌至关重要,它提供一致和可靠的结果。在资源有限的地区,hbcrag快速诊断试验(HBcrAg-RDT)有助于早期发现和管理HBV。这种即时检测(POCT)工具不需要专门的设备,可在30分钟内提供结果,在缺乏HBV DNA定量的地区非常宝贵。西非、亚洲和其他发展中地区的试验证明了其敏感性和特异性。总之,iTACT-HBcrAg和HBcrAg-RDT检测的这些进展加强了慢性乙型肝炎患者的护理,并为消除作为公共卫生威胁的乙型肝炎病毒的全球努力做出了重大贡献。
{"title":"Current global applications of HBcrAg assays in the management of chronic hepatitis B.","authors":"Takako Inoue, Yasuhito Tanaka","doi":"10.35772/ghm.2024.01097","DOIUrl":"https://doi.org/10.35772/ghm.2024.01097","url":null,"abstract":"<p><p>Hepatitis B core-related antigen (HBcrAg) is a vital marker for monitoring chronic hepatitis B (CHB) as it correlates with hepatitis B (HBV) DNA and covalently closed circular DNA (cccDNA). The iTACT-HBcrAg assay, approved in Japan, provides highly sensitive and automated testing, reducing patient burden by requiring smaller specimen volumes and offering shorter processing times. Crucial for managing HBV reactivation and predicting hepatocellular carcinoma, it delivers consistent and reliable results. In resource-limited regions, the HBcrAg-rapid diagnostic test (HBcrAg-RDT) facilitates early HBV detection and management. This point-of-care testing (POCT) tool requires no specialized equipment and provides results within 30 minutes, making it invaluable in areas lacking HBV DNA quantification. Trials in West Africa, Asia, and other developing regions demonstrate its sensitivity and specificity. Together, these advancements in iTACT-HBcrAg and HBcrAg-RDT assays enhance CHB patient care and contribute significantly to the global effort to eliminate HBV as a public health threat.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"7 1","pages":"67-71"},"PeriodicalIF":1.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychological support for people with hemophilia and HIV who suffer from cancer: A first national survey. 为罹患癌症的血友病患者和艾滋病患者提供心理支持:首次全国性调查。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2025-02-28 DOI: 10.35772/ghm.2024.01076
Akari Fukuda, Michiko Koga, Takahiro Tanaka, Aya Ishizaka, Takashi Hosaka, Hiroshi Yotsuyanagi

Psychological support is necessary for people with hemophilia and HIV (PHH) who suffer from cancers. Most PHH are infected with not only HIV but also hepatitis C virus due to non-heat-treated blood coagulation factor products. PHH have a high risk of carcinogenesis, including liver cancer. Furthermore, many PHH present psychological problems, due to the great stress resulting from carcinogenesis and which impedes their cancer treatment. This study aimed to assess the psychological support system through a nationwide survey of healthcare workers caring for PHH at HIV care hospitals in Japan. The response rate was 49.1% (194/395), with a coverage rate of 74% (516/697) for PHH. Our findings indicated that psychologists were the most likely to be "coordinated" or "expected to coordinate" when PHH suffered from cancer (74%, multiple responses allowed). The most common reason for rating the adequacy of psychological support as "very good" or "good" was "easy collaboration with various professionals and medical teams". The number of HIV coordinator nurses and clinical psychologists per facility was 1.06 and 2.56, respectively. Our findings indicated more psychological support systems should be established in Japan, including reimbursement for psychological support for PHH.

对于罹患癌症的血友病和艾滋病病毒感染者(PHH)来说,心理支持是必要的。由于使用未经热处理的血凝因子产品,大多数血友病患者不仅会感染艾滋病毒,还会感染丙型肝炎病毒。PHH 的致癌风险很高,包括肝癌。此外,许多 PHH 还存在心理问题,这是因为致癌物质给他们造成了巨大压力,阻碍了他们的癌症治疗。本研究旨在通过对日本 HIV 护理医院中护理 PHH 的医护人员进行全国性调查,评估心理支持系统。回复率为 49.1%(194/395),PHH 的覆盖率为 74%(516/697)。我们的调查结果表明,当 PHH 患有癌症时,心理学家最有可能 "进行协调 "或 "有望进行协调"(74%,允许多次回答)。将心理支持的充分性评为 "非常好 "或 "好 "的最常见原因是 "易于与各种专业人员和医疗团队合作"。每家机构的艾滋病协调护士和临床心理学家人数分别为 1.06 人和 2.56 人。我们的研究结果表明,日本应建立更多的心理支持系统,包括为 PHH 的心理支持提供补偿。
{"title":"Psychological support for people with hemophilia and HIV who suffer from cancer: A first national survey.","authors":"Akari Fukuda, Michiko Koga, Takahiro Tanaka, Aya Ishizaka, Takashi Hosaka, Hiroshi Yotsuyanagi","doi":"10.35772/ghm.2024.01076","DOIUrl":"https://doi.org/10.35772/ghm.2024.01076","url":null,"abstract":"<p><p>Psychological support is necessary for people with hemophilia and HIV (PHH) who suffer from cancers. Most PHH are infected with not only HIV but also hepatitis C virus due to non-heat-treated blood coagulation factor products. PHH have a high risk of carcinogenesis, including liver cancer. Furthermore, many PHH present psychological problems, due to the great stress resulting from carcinogenesis and which impedes their cancer treatment. This study aimed to assess the psychological support system through a nationwide survey of healthcare workers caring for PHH at HIV care hospitals in Japan. The response rate was 49.1% (194/395), with a coverage rate of 74% (516/697) for PHH. Our findings indicated that psychologists were the most likely to be \"coordinated\" or \"expected to coordinate\" when PHH suffered from cancer (74%, multiple responses allowed). The most common reason for rating the adequacy of psychological support as \"very good\" or \"good\" was \"easy collaboration with various professionals and medical teams\". The number of HIV coordinator nurses and clinical psychologists per facility was 1.06 and 2.56, respectively. Our findings indicated more psychological support systems should be established in Japan, including reimbursement for psychological support for PHH.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"7 1","pages":"39-48"},"PeriodicalIF":1.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative adjuvant chemotherapy in patients with gastric cancer based on the Nationwide Gastric Cancer Registry in Japan. 基于日本全国胃癌登记的胃癌患者术后辅助化疗。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2025-02-28 DOI: 10.35772/ghm.2024.01080
Yasuhide Yamada, Yasuyuki Seto, Takaki Yoshikawa, Hiroya Takeuchi, Yuko Kitagawa, Yasuhiro Kodera, Yuichiro Doki, Kazuhiro Yoshida, Kei Muro, Yoshinori Kabeya, Ami Kamada, Kengo Nagashima, Hiraku Kumamaru, Hisateru Tachimori, Mitsuru Sasako, Hitoshi Katai, Hiroyuki Konno, Yoshihiro Kakeji

The nationwide registry of the Japanese Gastric Cancer Association contains data related to the efficacy of adjuvant chemotherapy and prognostic factors across this patient population; elderly patients with advanced resectable gastric cancer are especially prevalent. Here, we analyzed data from 34,931 patients, who were treated between 2011 and 2013 at 421 hospitals in Japan. Although adjuvant chemotherapy was effective overall, 75 years or older elderly patients had a worse prognosis compared to younger patients. The most administered adjuvant chemotherapy was S-1 monotherapy. Adjuvant S-1 monotherapy was also effective for patients with pT1N2, pT1N3, and pT3N0 stage II tumors, as well as patients with other stage II and III malignancies. Independent prognostic factors for poor overall and relapse-free survival in patients at both stage II and stage III were age 75 or older, male, preoperative Eastern Cooperative Oncology Group performance status (ECOG-PS) 1 or more, preoperative renal dysfunction, undifferentiated adenocarcinoma, undergoing total gastrectomy, open laparotomy, no adjuvant chemotherapy, D1 lymphadenectomy, residual tumor R1 or R2, and Clavien-Dindo classification grade II or higher. Age 75 or older, renal dysfunction, ECOG-PS 1 and total gastrectomy were also significant risk factors for postoperative complications and lower compliance with adjuvant chemotherapy. Our analysis also revealed that adjuvant chemotherapy after resection of cancer of gastric remnant and postoperative chemotherapy against CY1 gastric cancer were also effective. We conclude that adjuvant chemotherapy is effective for all stage II and III patients including age 75 or older gastric cancer patients, in addition to distal gastrectomy, proximal gastrectomy, and pylorus-preserving surgery to avoid total gastrectomy may improve surgical outcomes and quality of life for elderly patients.

日本胃癌协会的全国注册包含与辅助化疗疗效和预后因素相关的数据;老年晚期可切除胃癌患者尤为普遍。在这里,我们分析了2011年至2013年期间在日本421家医院接受治疗的34,931名患者的数据。虽然辅助化疗总体上是有效的,但75岁及以上的老年患者与年轻患者相比预后更差。使用最多的辅助化疗是S-1单药治疗。辅助S-1单药治疗对pT1N2、pT1N3和pT3N0期肿瘤患者以及其他II期和III期恶性肿瘤患者也有效。II期和III期患者总生存率差和无复发生存率差的独立预后因素为:年龄75岁及以上、男性、术前东部肿瘤合作组表现状态(ECOG-PS) 1及以上、术前肾功能不全、未分化腺癌、行全胃切除术、开腹手术、无辅助化疗、D1淋巴结切除术、残留肿瘤R1或R2、Clavien-Dindo分级II级及以上。75岁及以上、肾功能不全、ecog - ps1和全胃切除术也是术后并发症和辅助化疗依从性较低的重要危险因素。我们的分析还显示残胃癌切除后的辅助化疗和CY1胃癌术后的化疗也是有效的。我们得出结论,辅助化疗对所有II期和III期患者(包括75岁及以上的胃癌患者)都是有效的,此外,远端胃切除术、近端胃切除术和保留幽门手术避免全胃切除术可以改善老年患者的手术效果和生活质量。
{"title":"Postoperative adjuvant chemotherapy in patients with gastric cancer based on the Nationwide Gastric Cancer Registry in Japan.","authors":"Yasuhide Yamada, Yasuyuki Seto, Takaki Yoshikawa, Hiroya Takeuchi, Yuko Kitagawa, Yasuhiro Kodera, Yuichiro Doki, Kazuhiro Yoshida, Kei Muro, Yoshinori Kabeya, Ami Kamada, Kengo Nagashima, Hiraku Kumamaru, Hisateru Tachimori, Mitsuru Sasako, Hitoshi Katai, Hiroyuki Konno, Yoshihiro Kakeji","doi":"10.35772/ghm.2024.01080","DOIUrl":"https://doi.org/10.35772/ghm.2024.01080","url":null,"abstract":"<p><p>The nationwide registry of the Japanese Gastric Cancer Association contains data related to the efficacy of adjuvant chemotherapy and prognostic factors across this patient population; elderly patients with advanced resectable gastric cancer are especially prevalent. Here, we analyzed data from 34,931 patients, who were treated between 2011 and 2013 at 421 hospitals in Japan. Although adjuvant chemotherapy was effective overall, 75 years or older elderly patients had a worse prognosis compared to younger patients. The most administered adjuvant chemotherapy was S-1 monotherapy. Adjuvant S-1 monotherapy was also effective for patients with pT1N2, pT1N3, and pT3N0 stage II tumors, as well as patients with other stage II and III malignancies. Independent prognostic factors for poor overall and relapse-free survival in patients at both stage II and stage III were age 75 or older, male, preoperative Eastern Cooperative Oncology Group performance status (ECOG-PS) 1 or more, preoperative renal dysfunction, undifferentiated adenocarcinoma, undergoing total gastrectomy, open laparotomy, no adjuvant chemotherapy, D1 lymphadenectomy, residual tumor R1 or R2, and Clavien-Dindo classification grade II or higher. Age 75 or older, renal dysfunction, ECOG-PS 1 and total gastrectomy were also significant risk factors for postoperative complications and lower compliance with adjuvant chemotherapy. Our analysis also revealed that adjuvant chemotherapy after resection of cancer of gastric remnant and postoperative chemotherapy against CY1 gastric cancer were also effective. We conclude that adjuvant chemotherapy is effective for all stage II and III patients including age 75 or older gastric cancer patients, in addition to distal gastrectomy, proximal gastrectomy, and pylorus-preserving surgery to avoid total gastrectomy may improve surgical outcomes and quality of life for elderly patients.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"7 1","pages":"13-27"},"PeriodicalIF":1.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-COVID-19 era trends in foreigners undergoing a complete medical examination in Japan: A single-center analysis of inbound medical care. 后新冠肺炎时代在日本接受全面体检的外国人的趋势:入境医疗服务的单中心分析
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2025-02-28 DOI: 10.35772/ghm.2025.01006
Jun Lu, Sachiko Kubo, Makiko Hashimoto, Yuko Hayashi, Erika Masuda, Miyuki Sadatsuki, Yukio Hiroi

In the post-COVID-19 era, inbound medical care in Japan adapted to the growing demand for high-quality and precise healthcare. One form of this care is a complete medical examination, which has gained significant popularity among foreign residents of Japan and foreign visitors to Japan. From 2021 to 2024, 787 individuals from 27 countries underwent a complete medical examination at our facility. The annual growth rate in foreign residents undergoing a complete medical examination was 64% (2022 vs. 2021), 22% (2023 vs. 2022), and 10% (2024 vs. 2023); a notable proportion of those individuals were originally from China. These findings underscore the need for Japan's medical care to evolve in response to the diverse needs of an international clientele, highlighting the importance of tailored healthcare solutions in a globalized context.

在后新冠肺炎时代,日本的入境医疗适应了对高质量和精准医疗日益增长的需求。这种护理的一种形式是全面的医疗检查,这在日本的外国居民和来日本的外国游客中非常受欢迎。从2021年到2024年,来自27个国家的787人在我们的设施接受了全面的体检。接受全面体检的外国居民年增长率分别为64%(2022年vs 2021年)、22%(2023年vs 2022年)和10%(2024年vs 2023年);这些人中有很大一部分来自中国。这些调查结果强调了日本的医疗保健需要发展以应对国际客户的多样化需求,突出了在全球化背景下定制医疗保健解决方案的重要性。
{"title":"Post-COVID-19 era trends in foreigners undergoing a complete medical examination in Japan: A single-center analysis of inbound medical care.","authors":"Jun Lu, Sachiko Kubo, Makiko Hashimoto, Yuko Hayashi, Erika Masuda, Miyuki Sadatsuki, Yukio Hiroi","doi":"10.35772/ghm.2025.01006","DOIUrl":"https://doi.org/10.35772/ghm.2025.01006","url":null,"abstract":"<p><p>In the post-COVID-19 era, inbound medical care in Japan adapted to the growing demand for high-quality and precise healthcare. One form of this care is a complete medical examination, which has gained significant popularity among foreign residents of Japan and foreign visitors to Japan. From 2021 to 2024, 787 individuals from 27 countries underwent a complete medical examination at our facility. The annual growth rate in foreign residents undergoing a complete medical examination was 64% (2022 <i>vs</i>. 2021), 22% (2023 <i>vs</i>. 2022), and 10% (2024 <i>vs</i>. 2023); a notable proportion of those individuals were originally from China. These findings underscore the need for Japan's medical care to evolve in response to the diverse needs of an international clientele, highlighting the importance of tailored healthcare solutions in a globalized context.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"7 1","pages":"74-76"},"PeriodicalIF":1.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV-1 protease inhibitors and mechanisms of HIV-1's resistance. HIV-1蛋白酶抑制剂和HIV-1耐药机制
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01073
Debananda Das

Current anti-HIV drugs have significantly improved the prognosis of HIV infected patients so much so that it is now considered a chronic disease, and adherence to medications keeps non-detectable amounts of the virus in the body. However, HIV is still able to generate drug resistance substitutions. Protease inhibitors (PIs) in combination with other classes of anti-HIV drugs constitute an important part of the anti-HIV drug regimen. This article discusses some of the common resistance substitutions against PIs, mechanistic insight on resistance, and potential new inhibitors that can show efficacy against current resistant variants.

目前的抗艾滋病毒药物已经显著改善了艾滋病毒感染者的预后,以至于它现在被认为是一种慢性疾病,坚持服用药物会使体内的病毒数量无法检测到。然而,艾滋病毒仍然能够产生耐药替代品。蛋白酶抑制剂(PIs)与其他类型的抗hiv药物联合使用是抗hiv药物方案的重要组成部分。本文讨论了一些针对pi的常见耐药替代品,耐药性的机制见解,以及可能对当前耐药变体有效的潜在新抑制剂。
{"title":"HIV-1 protease inhibitors and mechanisms of HIV-1's resistance.","authors":"Debananda Das","doi":"10.35772/ghm.2024.01073","DOIUrl":"10.35772/ghm.2024.01073","url":null,"abstract":"<p><p>Current anti-HIV drugs have significantly improved the prognosis of HIV infected patients so much so that it is now considered a chronic disease, and adherence to medications keeps non-detectable amounts of the virus in the body. However, HIV is still able to generate drug resistance substitutions. Protease inhibitors (PIs) in combination with other classes of anti-HIV drugs constitute an important part of the anti-HIV drug regimen. This article discusses some of the common resistance substitutions against PIs, mechanistic insight on resistance, and potential new inhibitors that can show efficacy against current resistant variants.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"357-362"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increase in the number of female doctors and the challenges that Japan's medical system must face. 女医生数量的增加和日本医疗系统必须面对的挑战。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01067
Shotaro Kinoshita, Taishiro Kishimoto

Japan has seen an increase in female physicians recently, yet it still lags behind other Organization for Economic Cooperation and Development (OECD) countries. A major barrier has been the historical discrimination against women in medical school admissions. In recent years, female enrolment in medical schools has risen, surpassing 40% in 2024, reflecting a broader societal shift. However, structural problems persist in the Japanese healthcare system. Although the number of doctors per capita is lower in Japan than in other countries, the number of patients is higher than in other countries, leading to overwork for doctors. As a result, only about one-third of female doctors in Japan are able to return to work after interrupting their careers to give birth or raise children. The maldistribution of physicians, both regionally and by specialty, exacerbates this issue. To sustain the rising number of female physicians, Japan must reform its medical system.

最近,日本的女医生有所增加,但仍落后于经济合作与发展组织(OECD)的其他国家。一个主要障碍是在医学院录取中对妇女的历史歧视。近年来,医学院的女性入学率有所上升,2024年超过40%,反映了更广泛的社会转变。然而,日本医疗体系的结构性问题依然存在。虽然日本的人均医生数量低于其他国家,但患者数量却高于其他国家,这导致了医生的过度劳累。因此,在日本,只有大约三分之一的女医生能够在中断职业生涯生育或抚养孩子后重返工作岗位。医生的分布不均,无论是地区还是专业,都加剧了这一问题。为了维持不断增长的女医生数量,日本必须改革其医疗体系。
{"title":"Increase in the number of female doctors and the challenges that Japan's medical system must face.","authors":"Shotaro Kinoshita, Taishiro Kishimoto","doi":"10.35772/ghm.2024.01067","DOIUrl":"10.35772/ghm.2024.01067","url":null,"abstract":"<p><p>Japan has seen an increase in female physicians recently, yet it still lags behind other Organization for Economic Cooperation and Development (OECD) countries. A major barrier has been the historical discrimination against women in medical school admissions. In recent years, female enrolment in medical schools has risen, surpassing 40% in 2024, reflecting a broader societal shift. However, structural problems persist in the Japanese healthcare system. Although the number of doctors per capita is lower in Japan than in other countries, the number of patients is higher than in other countries, leading to overwork for doctors. As a result, only about one-third of female doctors in Japan are able to return to work after interrupting their careers to give birth or raise children. The maldistribution of physicians, both regionally and by specialty, exacerbates this issue. To sustain the rising number of female physicians, Japan must reform its medical system.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"433-435"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of physical frailty and its associated factors among elderly patients undergoing hepatobiliary pancreatic surgery in China. 中国老年肝胆胰手术患者身体虚弱的患病率及其相关因素
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01089
Yi Deng, Rui Liao, Xiaofeng Hu, Keming Zhang, Jiali Zhu, Naomi Sato

Frailty is a geriatric syndrome characterized by a multisystem physiological decline, increased vulnerability to stressors, and adverse clinical outcomes. However, there is a knowledge gap regarding the association between frailty and its influencing factors. This study aimed to understand the current status of preoperative frailty in elderly patients with hepatobiliary pancreatic disease (HBP) and analyze debilitation-related factors. We enrolled 220 participants aged ≥ 65 years who underwent HBP surgery at two hospitals in China between December 2023 and February 2024. The physical frailty of elderly participants in communities with different characteristics was compared using Kruskal-Wallis and chi-square tests. Ordinal logistic regression analysis was used to analyze the factors influencing preoperative frailty. A total of 212 patients were included in the analysis based on the inclusion and exclusion criteria, with an overall prevalence of frailty at 53 (25%). Ordinal logistic regression analysis results showed that current smoking (odds ratio [OR] = 2.584, p = 0.006) was an independent risk factor for preoperative frailty in elderly participants with HBP. In contrast, exercise habits (OR = 0.323, p < 0.001), two or more multimorbidity statuses (OR = 0.495, p = 0.033), and independent status (OR = 0.216, p < 0.001) were protective factors. Our results suggest that having good exercise habits, not smoking, and independent status can prevent frailty progression in older adults who require HBP surgery. Interventions for frail elderly patients should be supported preoperatively by strengthening exercises to improve tolerance to surgery.

虚弱是一种老年综合征,其特征是多系统生理衰退,对压力源的易感性增加,以及不良的临床结果。然而,关于脆弱及其影响因素之间的关系,存在知识差距。本研究旨在了解老年肝胆胰疾病(HBP)患者术前虚弱的现状,并分析其相关因素。我们招募了220名年龄≥65岁的参与者,他们于2023年12月至2024年2月在中国的两家医院接受了HBP手术。采用Kruskal-Wallis检验和卡方检验比较不同特征社区老年参与者的身体虚弱程度。采用有序logistic回归分析术前虚弱的影响因素。根据纳入和排除标准,共有212例患者被纳入分析,总体虚弱患病率为53(25%)。有序logistic回归分析结果显示,当前吸烟(优势比[OR] = 2.584, p = 0.006)是老年高血压患者术前虚弱的独立危险因素。相反,运动习惯(OR = 0.323, p < 0.001)、两种及两种以上多病状态(OR = 0.495, p = 0.033)和独立状态(OR = 0.216, p < 0.001)是保护因素。我们的研究结果表明,良好的运动习惯、不吸烟和独立状态可以预防需要高血压手术的老年人的虚弱进展。对老年体弱患者术前应加强锻炼以提高手术耐受性。
{"title":"Prevalence of physical frailty and its associated factors among elderly patients undergoing hepatobiliary pancreatic surgery in China.","authors":"Yi Deng, Rui Liao, Xiaofeng Hu, Keming Zhang, Jiali Zhu, Naomi Sato","doi":"10.35772/ghm.2024.01089","DOIUrl":"10.35772/ghm.2024.01089","url":null,"abstract":"<p><p>Frailty is a geriatric syndrome characterized by a multisystem physiological decline, increased vulnerability to stressors, and adverse clinical outcomes. However, there is a knowledge gap regarding the association between frailty and its influencing factors. This study aimed to understand the current status of preoperative frailty in elderly patients with hepatobiliary pancreatic disease (HBP) and analyze debilitation-related factors. We enrolled 220 participants aged ≥ 65 years who underwent HBP surgery at two hospitals in China between December 2023 and February 2024. The physical frailty of elderly participants in communities with different characteristics was compared using Kruskal-Wallis and chi-square tests. Ordinal logistic regression analysis was used to analyze the factors influencing preoperative frailty. A total of 212 patients were included in the analysis based on the inclusion and exclusion criteria, with an overall prevalence of frailty at 53 (25%). Ordinal logistic regression analysis results showed that current smoking (odds ratio [OR] = 2.584, <i>p</i> = 0.006) was an independent risk factor for preoperative frailty in elderly participants with HBP. In contrast, exercise habits (OR = 0.323, <i>p</i> < 0.001), two or more multimorbidity statuses (OR = 0.495, <i>p</i> = 0.033), and independent status (OR = 0.216, <i>p</i> < 0.001) were protective factors. Our results suggest that having good exercise habits, not smoking, and independent status can prevent frailty progression in older adults who require HBP surgery. Interventions for frail elderly patients should be supported preoperatively by strengthening exercises to improve tolerance to surgery.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"394-403"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan. 日本过敏人群对mRNA - COVID-19疫苗的不良反应
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01053
Naoko Shoji, Suminobu Ito, Shuko Nojiri, Wataru Urasaki, Tamaki Nara, Atsushi Okuzawa, Morikuni Tobita

mRNA vaccines emerged as a new therapeutic modality during the COVID-19 pandemic. Individuals with allergies often experience anxiety about potential adverse reactions to these vaccines. This study aims to elucidate the relationship between adverse reactions and various allergies, asthma, or atopic disorders. Data from approximately 20,000 Japanese healthcare workers participating in a prospective cohort study were analyzed. The number of vaccinated individuals was 19,792 (first dose), with systemic reactions occurring in 35.8% after the first dose and 75.3% after the second dose. Participants with allergies were categorized into groups: food and/or drug allergies (n = 806), asthma and/or atopic disorders (n = 2,370), asthma (both past medical history [PMH] and present illness [PI]) (n = 1,983), and atopic disorders (PI) (n = 567). Most systemic reactions in those with food and/or drug allergies occurred within the first three days of vaccination. Logistic regression analysis showed that food and/or drug allergies, asthma (PMH and PI), and asthma and/or atopic disorders were significantly associated with systemic reactions (odds ratios [95% confidence interval]: 1.65 [1.43-1.91], 1.36 [1.23-1.49], and 1.32 [1.21-1.45], respectively, for the first dose). These findings suggest the risk of systemic reactions after COVID-19 vaccination in individuals with the specified allergies, potentially contributing to vaccine hesitancy. Medical professionals should clearly communicate the risks and benefits of vaccination to those with allergies to alleviate their concerns. Additionally, our study's data may be useful for making decisions whether or not to get vaccinated in those with allergies and inform the development of future mRNA vaccines.

mRNA疫苗在COVID-19大流行期间成为一种新的治疗方式。有过敏症的人通常会对这些疫苗的潜在不良反应感到焦虑。本研究旨在阐明不良反应与各种过敏、哮喘或特应性疾病之间的关系。研究人员分析了参与前瞻性队列研究的约20,000名日本医护人员的数据。接种人数为19,792人(首次接种),第一次接种后发生全身反应的人数为35.8%,第二次接种后发生全身反应的人数为75.3%。过敏症患者被分为食物和/或药物过敏(n = 806)、哮喘和/或特应性疾病(n = 2370)、哮喘(既往病史[PMH]和目前疾病[PI]) (n = 1983)和特应性疾病(n = 567)。大多数对食物和/或药物过敏的人的全身反应发生在接种疫苗的前三天。Logistic回归分析显示,食物和/或药物过敏、哮喘(PMH和PI)、哮喘和/或特应性疾病与全身反应显著相关(首次剂量的比值比[95%置信区间]分别为1.65[1.43-1.91]、1.36[1.23-1.49]和1.32[1.21-1.45])。这些发现表明,特定过敏症患者接种COVID-19疫苗后出现全身反应的风险,可能导致疫苗犹豫。医疗专业人员应明确告知过敏人群接种疫苗的风险和益处,以减轻他们的担忧。此外,我们的研究数据可能有助于决定过敏患者是否接种疫苗,并为未来mRNA疫苗的开发提供信息。
{"title":"Adverse reactions to mRNA COVID-19 vaccine in people with allergies in Japan.","authors":"Naoko Shoji, Suminobu Ito, Shuko Nojiri, Wataru Urasaki, Tamaki Nara, Atsushi Okuzawa, Morikuni Tobita","doi":"10.35772/ghm.2024.01053","DOIUrl":"10.35772/ghm.2024.01053","url":null,"abstract":"<p><p>mRNA vaccines emerged as a new therapeutic modality during the COVID-19 pandemic. Individuals with allergies often experience anxiety about potential adverse reactions to these vaccines. This study aims to elucidate the relationship between adverse reactions and various allergies, asthma, or atopic disorders. Data from approximately 20,000 Japanese healthcare workers participating in a prospective cohort study were analyzed. The number of vaccinated individuals was 19,792 (first dose), with systemic reactions occurring in 35.8% after the first dose and 75.3% after the second dose. Participants with allergies were categorized into groups: food and/or drug allergies (<i>n</i> = 806), asthma and/or atopic disorders (<i>n</i> = 2,370), asthma (both past medical history [PMH] and present illness [PI]) (<i>n</i> = 1,983), and atopic disorders (PI) (<i>n</i> = 567). Most systemic reactions in those with food and/or drug allergies occurred within the first three days of vaccination. Logistic regression analysis showed that food and/or drug allergies, asthma (PMH and PI), and asthma and/or atopic disorders were significantly associated with systemic reactions (odds ratios [95% confidence interval]: 1.65 [1.43-1.91], 1.36 [1.23-1.49], and 1.32 [1.21-1.45], respectively, for the first dose). These findings suggest the risk of systemic reactions after COVID-19 vaccination in individuals with the specified allergies, potentially contributing to vaccine hesitancy. Medical professionals should clearly communicate the risks and benefits of vaccination to those with allergies to alleviate their concerns. Additionally, our study's data may be useful for making decisions whether or not to get vaccinated in those with allergies and inform the development of future mRNA vaccines.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"363-374"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-specific brain fluorodeoxyglucose positron emission tomography can detect the first effects of combination antiretroviral therapy in patient with HIV infection. 患者特异性脑氟脱氧葡萄糖正电子发射断层扫描可以检测艾滋病毒感染患者联合抗逆转录病毒治疗的首次效果。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01039
Miyako M Chikanishi, Junko Tanuma, Kenji Ishii, Muneyuki Sakata, Noritoshi Arai, Tomoyuki Noguchi, Kensuke Komatsu, Kimiteru Ito, Tetsuya Mizoue, Kazuo Kubota, Takeyuki Watadani, Hiroyuki Gatanaga, Shinichi Oka

Patient-specific brain fluorodeoxyglucose-positron emission tomography (FDG PET) can detect areas with abnormal FDG uptake in patients with human immunodeficiency virus (HIV) before and after combination antiretroviral therapy (cART). There were few reports about the same patients before and shortly after cART in FDG PET. It is well known that HIV-RNA levels decrease and cognitive impairments in patients with HIV tend to improve on neurocognitive performance tests 6 months after starting cART. We conducted a quantitative imaging analysis (FDG PET and voxel-based morphometry (VBM)) of eight patients at pre- and 6 months post- cART with neurocognitive performance tests. In terms of participant-specific changes between pre- and post-cART imaging, some area showed that the size of area with abnormal FDG uptake shrunk and became a nearly physiological level at 6 months post-cART. No apparent changes in VBM were observed in this short period. FDG PET might detect the first effect of cART.

患者特异性脑氟脱氧葡萄糖正电子发射断层扫描(FDG PET)可以检测人类免疫缺陷病毒(HIV)患者在联合抗逆转录病毒治疗(cART)前后FDG摄取异常的区域。在FDG PET中,很少有相同患者在cART之前和之后不久的报道。众所周知,在开始cART治疗6个月后,HIV- rna水平下降,HIV患者的认知障碍倾向于在神经认知性能测试中改善。我们对8名患者在cART术前和术后6个月进行了定量成像分析(FDG PET和基于体素的形态测定法(VBM)),并进行了神经认知表现测试。在cart前后的参与者特异性变化方面,部分区域显示FDG摄取异常区域的大小在cart后6个月缩小并接近生理水平。在这短时间内未观察到VBM的明显变化。FDG PET可以检测到cART的第一效应。
{"title":"Patient-specific brain fluorodeoxyglucose positron emission tomography can detect the first effects of combination antiretroviral therapy in patient with HIV infection.","authors":"Miyako M Chikanishi, Junko Tanuma, Kenji Ishii, Muneyuki Sakata, Noritoshi Arai, Tomoyuki Noguchi, Kensuke Komatsu, Kimiteru Ito, Tetsuya Mizoue, Kazuo Kubota, Takeyuki Watadani, Hiroyuki Gatanaga, Shinichi Oka","doi":"10.35772/ghm.2024.01039","DOIUrl":"10.35772/ghm.2024.01039","url":null,"abstract":"<p><p>Patient-specific brain fluorodeoxyglucose-positron emission tomography (FDG PET) can detect areas with abnormal FDG uptake in patients with human immunodeficiency virus (HIV) before and after combination antiretroviral therapy (cART). There were few reports about the same patients before and shortly after cART in FDG PET. It is well known that HIV-RNA levels decrease and cognitive impairments in patients with HIV tend to improve on neurocognitive performance tests 6 months after starting cART. We conducted a quantitative imaging analysis (FDG PET and voxel-based morphometry (VBM)) of eight patients at pre- and 6 months post- cART with neurocognitive performance tests. In terms of participant-specific changes between pre- and post-cART imaging, some area showed that the size of area with abnormal FDG uptake shrunk and became a nearly physiological level at 6 months post-cART. No apparent changes in VBM were observed in this short period. FDG PET might detect the first effect of cART.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"420-426"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of oral allylestrenol in women with recurrent spontaneous abortion: A retrospective clinical trial. 口服烯丙雌醇治疗复发性自然流产:一项回顾性临床试验。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-12-31 DOI: 10.35772/ghm.2024.01056
Jing Wang, Lisha Li, Jing Zhou, Xinyao Pan, Qing Qi, Hongmei Sun, Ming Liu, Ling Wang

Recurrent spontaneous abortion (RSA), defined as two or more clinically confirmed pregnancies that end before 20-24 weeks of gestation, encompasses both embryonic and fetal losses and is a significant clinical challenge. The aim of this study was to compare the efficacy of allylestrenol (AT) and progesterone in improving pregnancy outcomes in RSA. From June 2021 to June 2024, 480 participants were randomly assigned to an AT, Progesterone, or Control group. Key outcomes included early pregnancy rates, ongoing pregnancies with fetal heart activity, live birth rates after 24 weeks, and pregnancy loss before 24 weeks. Results indicated significantly higher pregnancy rates at 6-8 weeks in both the Allylestrenol (71.8%) and Progesterone groups (76.2%) compared to the Control group (57.5%). At 12 weeks, ongoing pregnancies with fetal heart activity were higher in the Allylestrenol (65%) and Progesterone groups (64%) versus the Control group (52.5%). Both treatment groups had higher live birth rates (60% and 60.6%) compared to the Control group (45%). Pregnancy loss before 24 weeks was lower in both treatment groups (31.8% and 33.1%) compared to the Control group (38.7%). No significant adverse reactions were observed, indicating good safety profiles for both treatments. These findings suggest that both treatments effectively improve pregnancy outcomes in cases of RSA with satisfactory safety, supporting their potential clinical use. However, further research is needed to explore their long-term effects and broader applicability in clinical settings.

复发性自然流产(RSA),定义为两次或两次以上临床证实的妊娠,在妊娠20-24周之前结束,包括胚胎和胎儿丢失,是一个重大的临床挑战。本研究的目的是比较烯丙雌醇(AT)和黄体酮在改善RSA妊娠结局方面的疗效。从2021年6月到2024年6月,480名参与者被随机分配到AT组、黄体酮组或对照组。主要结局包括早孕率、持续妊娠并伴有胎儿心脏活动、24周后的活产率和24周前的流产率。结果显示,与对照组(57.5%)相比,烯丙雌醇组(71.8%)和黄体酮组(76.2%)在6-8周的妊娠率均显著高于对照组(71.8%)。在妊娠12周时,烯丙雌醇组(65%)和黄体酮组(64%)的胎儿心脏活动高于对照组(52.5%)。两个治疗组的活产率(60%和60.6%)均高于对照组(45%)。与对照组(38.7%)相比,两个治疗组在24周前的妊娠损失(31.8%和33.1%)较低。没有观察到明显的不良反应,表明两种治疗方法的安全性都很好。这些发现表明,这两种治疗方法都有效地改善了RSA病例的妊娠结局,并具有令人满意的安全性,支持其潜在的临床应用。然而,需要进一步的研究来探索它们的长期效果和在临床环境中更广泛的适用性。
{"title":"Use of oral allylestrenol in women with recurrent spontaneous abortion: A retrospective clinical trial.","authors":"Jing Wang, Lisha Li, Jing Zhou, Xinyao Pan, Qing Qi, Hongmei Sun, Ming Liu, Ling Wang","doi":"10.35772/ghm.2024.01056","DOIUrl":"10.35772/ghm.2024.01056","url":null,"abstract":"<p><p>Recurrent spontaneous abortion (RSA), defined as two or more clinically confirmed pregnancies that end before 20-24 weeks of gestation, encompasses both embryonic and fetal losses and is a significant clinical challenge. The aim of this study was to compare the efficacy of allylestrenol (AT) and progesterone in improving pregnancy outcomes in RSA. From June 2021 to June 2024, 480 participants were randomly assigned to an AT, Progesterone, or Control group. Key outcomes included early pregnancy rates, ongoing pregnancies with fetal heart activity, live birth rates after 24 weeks, and pregnancy loss before 24 weeks. Results indicated significantly higher pregnancy rates at 6-8 weeks in both the Allylestrenol (71.8%) and Progesterone groups (76.2%) compared to the Control group (57.5%). At 12 weeks, ongoing pregnancies with fetal heart activity were higher in the Allylestrenol (65%) and Progesterone groups (64%) versus the Control group (52.5%). Both treatment groups had higher live birth rates (60% and 60.6%) compared to the Control group (45%). Pregnancy loss before 24 weeks was lower in both treatment groups (31.8% and 33.1%) compared to the Control group (38.7%). No significant adverse reactions were observed, indicating good safety profiles for both treatments. These findings suggest that both treatments effectively improve pregnancy outcomes in cases of RSA with satisfactory safety, supporting their potential clinical use. However, further research is needed to explore their long-term effects and broader applicability in clinical settings.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 6","pages":"427-432"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Global health & medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1